Table 1.
Group | IL-1β/pg·mL−1 | TNF-α/pg·mL−1 | IFN-γ/pg·mL−1 |
---|---|---|---|
A group | 217.39±61.22 | 135.20±17.86 | 154.23±43.04 |
B group | 731.26±156.34### | 164.24±18.82# | 506.03±191.55## |
C1 group | 547.62±172.16∗ | 145.05±17.85 | 198.84±54.15∗∗ |
C2 group | 262.96±191.44∗∗∗ | 143.20±18.85 | 182.98±88.86∗∗ |
D1 group | 535.62±154.12∗ | 146.37±24.72 | 209.58±69.74∗ |
D2 group | 375.62±143.54∗∗∗ | 148.54±26.84 | 186.47±71.19∗∗ |
Dexamethasone group | 239.42±102.37∗∗∗ | 140.30±19.10∗ | 185.88±67.94∗∗ |
Significant differences were based on independent sample t-test.
# P < 0.05, compared with control group; ##P < 0.01, compared with control group; ###P < 0.001, compared with control group.
∗ P < 0.05, compared with model group; ∗∗P < 0.01, compared with model group; ∗∗∗P < 0.001, compared with model group
Healthy control group (A). AIA model group (B). Therapy group (C1). Efficacy enhancing combination group (C2). Toxicity group (D1). Toxicity reducing combination group (D2). Dexamethasone group (DG).